Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nucletron BV

Division of Elekta AB
www.nucletron.com

Latest From Nucletron BV

New Products: Biotronik, Baxano, Medtronic Make Launch Announcements

The Ilesto Dx is the first of the small-sized Ilesto devices launched since their approval in May. Baxano expects modification of iO-Flex MicroBlade Shaver to be well-received during full launch. More product news.

Medical Device

Device Trends To Watch In 2012

For much of the device industry, 2011 was marked by continuing change across the medtech ecosystem, most notably in the economy, the regulatory process, and the financing/innovation model. For 2012, we predict more of the same: the only certainty is continuing uncertainty.

Medical Device Strategy

Deals Shaping the Medical Industry (07/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions.

Frontiers in Breast Cancer Research, Part II: Developments in Partial Breast Irradiation and Tumor Ablation

As the use of breast conserving lumpectomy expands as a treatment for early-stage breast cancer, interest has surged in alternatives to whole breast irradiation. Follow-on radiation treatment is crucial to the success of this therapy, but a significant number of women are either unable or unwilling to undergo the typical treatment course involving five to seven weeks of daily radiation therapy. The device industry is responding with technologies aimed at delivering post-lumpectomy radiation therapy in a more convenient, potentially safer way.
Medical Device
See All

Company Information

  • Industry
  • Medical Devices
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Netherlands
  • Parent & Subsidiaries
  • Elekta AB
  • Senior Management
  • Contact Info
  • Nucletron BV
    Phone: (31) 318 557 133
    Waardgelder 1
    3905
    Veenendaal, 3900 AX
    Netherlands
Advertisement
Advertisement
UsernamePublicRestriction

Register